Tylenol-maker Kenvue shares bounce, Trump claims face pushback

Kenvue (KVUE.N) shares in Frankfurt rose 6%, rebounding from a record low, despite former President Trump linking its Tylenol product to autism risk during pregnancy. While Kenvue and medical professionals reject a scientific link, and the FDA, though updating labels for a *possible* association, stresses no causal relationship is established, analysts anticipate limited judicial risk but potential negative impact on Tylenol consumption due to headlines.

Analysis

Kenvue's Frankfurt-listed shares (KVUE.N) demonstrated significant volatility, rebounding 6% from a record low despite negative headlines linking its Tylenol product to autism risk. The recovery was supported by analyst commentary from Citi, which anticipates limited judicial risk due to the absence of new scientific evidence, although they caution that negative headlines could still impact Tylenol consumption. The regulatory landscape is nuanced; while the U.S. Food and Drug Administration (FDA) will update labels to reflect a *possible* link between acetaminophen use during pregnancy and neurological conditions, it explicitly stated that no causal relationship has been established. This official clarification likely tempered investor fears of immediate, severe litigation fallout. Kenvue has maintained its position that no scientific link exists. Despite the single-day gain, the stock's 22.6% year-to-date decline in Frankfurt underscores persistent investor concerns and broader headwinds preceding this event.

Key Decisions for Investors

• Investors should closely monitor consumer sales data for Tylenol and related acetaminophen products, as the primary risk identified by analysts is a potential decline in consumption due to negative perception, not immediate legal liability.
• While the market appears to be pricing in limited judicial risk, the FDA's decision to update product labels introduces a long-term regulatory and litigation overhang that warrants close observation for any emerging lawsuits or scientific studies.
• Given the stock's rebound from a record low and its significant 22.6% year-to-date underperformance, investors might consider the current valuation in the context of headline-driven risk versus the company's fundamental performance, as the market's worst fears have not been confirmed.